Although the development of antibody drug conjugates (ADCs), ASCO (American Society of Clinical Oncology) guideline indicated that the dual HER2-targeted treatment including pertuzumab and trastuzumab, additional chemotherapy (taxane) remained the first-line standard therapy for patients with HER2 + BC [17]. The gene discussed is ERBB2; the disease is breast cancer.